Case ReportRenal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma
References (10)
- et al.
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Biochem Biophys Res Commun
(2005) - et al.
The role of vascular endothelial growth factor (VEGF) in renal pathophysiology
Kidney Int
(2004) - et al.
A new model of renal microvascular endothelial injury
Kidney Int
(1997) - et al.
Clinical cancer advances 2005: major research advances in cancer treatment, prevention and screening: a report from the American society of clinical oncology
J Clin Oncol
(2006) - et al.
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
J Clin Oncol
(2006)
There are more references available in the full text version of this article.
Cited by (127)
Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents
2021, Advances in Chronic Kidney DiseaseAnticancer Drugs and the Kidney
2019, Critical Care Nephrology: Third EditionThrombotic microangiopathy and cancer
2017, Nephrologie et TherapeutiqueCollapsing glomerulopathy is common in the setting of thrombotic microangiopathy of the native kidney
2016, Kidney InternationalThrombotic Microangiopathy, Cancer, and Cancer Drugs
2015, American Journal of Kidney Diseases
Copyright © 2007 Elsevier Ltd. All rights reserved.